Healthcare Triangle, Inc.
Healthcare Triangle, Inc. (HCTI) Financial Performance & Income Statement Overview
Review Healthcare Triangle, Inc. (HCTI) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Healthcare Triangle, Inc. (HCTI) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Healthcare Triangle, Inc. HCTI financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $3.70M | $2.19M | $2.41M | $2.98M |
| Cost of Revenue | $3.38M | $1.93M | $1.69M | $2.09M |
| Gross Profit | $329000.00 | $256000.00 | $722000.00 | $898000.00 |
| Gross Profit Ratio | $0.09 | $0.12 | $0.30 | $0.30 |
| R&D Expenses | $144000.00 | -$80000.00 | $175000.00 | $207000.00 |
| SG&A Expenses | $1.57M | $1.19M | $1.37M | $1.53M |
| Operating Expenses | $1.73M | $754000.00 | $1.89M | $2.28M |
| Total Costs & Expenses | $5.10M | $2.69M | $3.58M | $4.36M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $413000.00 | $853000.00 | $80000.00 | $131000.00 |
| Depreciation & Amortization | $12000.00 | -$145000.00 | $343000.00 | $534000.00 |
| EBITDA | -$1.27M | -$636000.00 | -$824000.00 | -$844000.00 |
| EBITDA Ratio | -$0.34 | -$0.29 | -$0.34 | -$0.28 |
| Operating Income | -$1.40M | -$498000.00 | -$1.17M | -$1.38M |
| Operating Income Ratio | -$0.38 | -$0.23 | -$0.48 | -$0.46 |
| Other Income/Expenses (Net) | -$302000.00 | -$846000.00 | -$80000.00 | -$131000.00 |
| Income Before Tax | -$1.70M | -$1.34M | -$1.25M | -$1.51M |
| Income Before Tax Ratio | -$0.46 | -$0.61 | -$0.52 | -$0.51 |
| Income Tax Expense | $0.00 | $4000.00 | $2000.00 | $1000.00 |
| Net Income | -$1.70M | -$1.35M | -$1.25M | -$1.51M |
| Net Income Ratio | -$0.46 | -$0.62 | -$0.52 | -$0.51 |
| EPS | -$0.004 | -$0.003 | -$0.003 | -$0.004 |
| Diluted EPS | -$0.004 | -$0.003 | -$0.003 | -$0.004 |
| Weighted Avg Shares Outstanding | $408.008M | $408.008M | $407.97M | $382.78M |
| Weighted Avg Shares Outstanding (Diluted) | $408.008M | $408.008M | $407.97M | $382.78M |
The company's financials show resilient growth, with revenue advancing from $2.98M in Q2 2024 to $3.70M in Q1 2025. Gross profit remained healthy with margins at 9% in Q1 2025 compared to 30% in Q2 2024. Operating income hit -$1.40M last quarter, sustaining a consistent -38% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.27M. Net income dropped to -$1.70M, while earnings per share reached -$0.004. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan